Results 31 to 40 of about 472,035 (296)

CECOG experts' recommendations on the use of denosumab in the prevention of skeletal-related events in bone metastases of lung cancer [PDF]

, 2013
Purpose Skeletal-related events represent a substantial burden for patients with advanced cancer. Randomized, controlled studies suggested superiority of denosumab over zoledronic acid in the prevention of skeletal-related events in metastatic cancer ...
Bachouchi, Mounir, Kalinka-Warzocha, Eva, Tamasi, Lila, Mohn-Staudner, Andrea, Aebersold, Daniel M., Brodowicz, Thomas, Yumuk, Fulden, Gaafar, Rabab, Holzer, Gerold, Kovac, Viljem, Siano, Marco, Hilbe, Wolfgang, Abacioglu, Ufuk, Kalev, Dimitar   +13 more
core   +1 more source

The molecular dissection of the regulation of PGC-1α and the genome-wide activity of its transcriptional network in skeletal muscle cells [PDF]

, 2013
The transcriptional coactivator peroxisome proliferator-activated receptor γ coactivator 1α (PGC-1α) is a potent inducer of mitochondrial biogenesis and oxidative metabolism.
Barešić, Mario
core   +1 more source

An Italian survey on the use of denosumab for the management of skeletal-related events in patients with bone metastases [PDF]

, 2022
The Italian Association for Medical Oncology (AIOM) recommends preventive treatment of skeletal-related events in order to improve survival and the quality of life of patients with advanced malignancies.
Berardi, R, Berruti, A, Zucali, P A, Brogelli, L   +3 more
core   +1 more source

Health state utilities for skeletal-related events secondary to bone metastases [PDF]

The European Journal of Health Economics, 2013
Patients with bone metastases often experience skeletal-related events (SREs). Although cost-utility models are used to examine treatments for metastatic cancer, limited information is available on utilities of SREs. The purpose of this study was to estimate the disutility of four SREs: spinal cord compression, pathological fracture, radiation to bone,
Matza, L.S., Chung, K., Van Brunt, K., Brazier, J.E., Braun, A., Currie, B., Palsgrove, A., Davies, E., Body, J.-J.   +8 more
openaire   +4 more sources

Statins may decrease skeletal-related events in breast cancer patients with bone metastases [PDF]

, 2006
Metastasis to the skeleton frequently occurs in breast carcinoma patients resulting in different skeletal-related events including pain, hypercatcemia, pathological fracture, and spinal cord or nerve root compression.
Bulut, Nilufer, Altundag, Kadri, Harputluoglu, Hakan, Dincer, Murat   +3 more
core   +1 more source

Risk of skeletal related events among elderly prostate cancer patients by site of metastasis at diagnosis

Cancer Medicine, 2016
The purpose of this study was to estimate the risk of developing skeletal‐related events (SREs) based on site of metastasis at diagnosis and identify other predictors of developing SREs among metastatic prostate cancer patients.
Arif Hussain, Abdalla Aly, C. Daniel Mullins, Yi Qian, Jorge Arellano, Eberechukwu Onukwugha   +5 more
doaj   +1 more source

Systematic review of the clinical effectiveness and cost-effectiveness, and economic evaluation, of denosumab for the treatment of bone metastases from solid tumours [PDF]

, 2013
Peer ...
Cummins, E., Cummins, E, R Johnston, Jones, R, Todd, R, Royle, P., Ford, J, Royle, P, F Stewart, Elders, A, E Cummins, Mowatt, G., J Ford, Todd, R., A Elders, Mowatt, G, Mulatero, C., P Royle, P Sharma, R Jones, Sharma, P., Elders, A., R Todd, Stewart, F, Mulatero, C, G Mowatt, Ford, J., Stewart, F., Sharma, P, C Mulatero, Johnston, R, Johnston, R., Jones, R.   +32 more
core   +1 more source

Bone Metastases and Skeletal-Related Events in Medullary Thyroid Carcinoma

The Journal of Clinical Endocrinology & Metabolism, 2016
Bone metastases (BM) can lead to devastating skeletal-related events (SREs) in cancer patients. Data regarding medullary thyroid carcinoma (MTC) with BM are lacking.We evaluated the natural history of BM and SREs in MTC patients identified by a cancer center tumor registry.The study was conducted at a tertiary cancer center.We retrospectively reviewed ...
Jian Yu, Xu, William A, Murphy, Denái R, Milton, Camilo, Jimenez, Sarika N, Rao, Mouhammed Amir, Habra, Steven G, Waguespack, Ramona, Dadu, Robert F, Gagel, Anita K, Ying, Maria E, Cabanillas, Steven P, Weitzman, Naifa L, Busaidy, Rena V, Sellin, Elizabeth, Grubbs, Steven I, Sherman, Mimi I, Hu   +16 more
openaire   +3 more sources

Optimizing skeletal‐related events prevention in patients with advanced prostate cancer [PDF]

Asia-Pacific Journal of Clinical Oncology, 2020
AbstractIn patients with metastatic castration‐resistant prostate cancer (mCRPC), bone is a dominant site of metastasis. Bone metastases often lead to skeletal‐related events (SREs), which include pain, spinal cord compression and fractures. The treatment of bone metastases in men with mCRPC aims to improve SRE‐free survival, quality of life and ...
openaire   +2 more sources

Are bone targeted agents still useful in times of immunotherapy? The SAKK 80/19 BTA pilot study

Bone Reports
Background: Patients with bone metastases from solid tumors often have additional treatment with bone targeted agents (BTAs) to avoid symptomatic skeletal events (SSEs) such as clinically significant pathological fracture leading toradiation therapy or ...
Michael Mark, Alfonso Rojas Mora, Thomas Winder, Anastasios Stathis, Andreas Jakob, Gisela Müller, Stefanie Hayoz, Patrick Reimann, Ulf Petrausch, Roger von Moos   +9 more
doaj   +1 more source